Trial reportOphthalmology2018
A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments.
Trial report in Ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02390531 (Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity), which is not on this map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.
- Pooled it
- Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity.JAMA ophthalmology · 2020Trial
- Temporal Changes in Screen-Detected Retinopathy of Prematurity Among Screened Very-Low-Birth-Weight Infants Born Before 32 Weeks of Gestation: A Single-Center Retrospective Cohort Study.Children (Basel, Switzerland) · 2026Article
- Beyond anti-VEGF: expanding the therapeutic horizon and biomarker landscape in retinopathy of prematurity.Frontiers in pediatrics · 2025Review
- Review
- Review
- Efficacy comparison of anti-vascular endothelial growth factor drugs for the treatment of type 1 retinopathy of prematurity: A network meta-analysis of randomised controlled trials.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Review
- Extending Peripheral Retinal Vascularization in Retinopathy of Prematurity Through Regulation of VEGF Signaling.American journal of ophthalmology · 2024Article
- Comparing reactivation and retreatment for three doses of bevacizumab in type 1 retinopathy of prematurity.Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus · 2024Article
- The incidence of retinopathy of prematurity in neonates in Germany in 2019; a nationwide epidemiological cohort study.European journal of pediatrics · 2024Article
- Efficacy of an Indian Bevacizumab BIOSimilar (BEVATAS) for Type 1 and Aggressive Posterior Retinopathy of Prematurity (BIOS-ROP Study).Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Analysis of research hotspots and trends in pediatric ophthalmopathy based on 10 years of WoSCC literature.Frontiers in pediatrics · 2024Article
- Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity: A Multicenter Study.Ophthalmology · 2023Article
- Article
- Systemic Cytokines in Retinopathy of Prematurity.Journal of personalized medicine · 2023Review
- Ocular and developmental outcomes of a dosing study of bevacizumab for retinopathy of prematurity.Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus · 2023Article
- Role of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) in the Treatment of Retinopathy of Prematurity: A Narrative Review in the Context of Middle-Income Countries.Pediatric health, medicine and therapeutics · 2023Review
- Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity.Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus · 2022Article
- Article
- A Review on the Incidence and Related Risk Factors of Retinopathy of Prematurity Across Various Countries.Cureus · 2022Review
Corrections and comments
- Commented on by
Authors and funding
12 authors at 7 institutions in 1 country.
Funding
Abstract
purposeIntravitreal bevacizumab is increasingly used to treat severe retinopathy of prematurity (ROP), but it enters the bloodstream, and there is concern that it may alter development of other organs. Previously we reported short-term outcomes of 61 infants enrolled in a dose de-escalation study, and we report the late recurrences and additional treatments.
designMasked, multicenter, dose de-escalation study.
participantsA total of 61 premature infants with type 1 ROP.
methodsIf type 1 ROP was bilateral at enrollment, then the study eye was randomly selected. In the study eye, bevacizumab intravitreal injections were given at de-escalating doses of 0.25 mg, 0.125 mg, 0.063 mg, or 0.031 mg; if needed, fellow eyes received 1 dose level higher: 0.625 mg, 0.25 mg, 0.125 mg, or 0.063 mg, respectively. After 4 weeks, additional treatment was at the discretion of the investigator.
main outcome measuresEarly and late ROP recurrences, additional treatments, and structural outcomes after 6 months.
resultsOf 61 study eyes, 25 (41%; 95% confidence interval [CI], 29%-54%) received additional treatment: 3 (5%; 95% CI, 1%-14%) for early failure (within 4 weeks), 11 (18%; 95% CI, 9%-30%) for late recurrence of ROP (after 4 weeks), and 11 (18%; 95% CI, 9%-30%) for persistent avascular retina. Re-treatment for early failure or late recurrence occurred in 2 of 11 eyes (18%; 95% CI, 2%-52%) treated with 0.25 mg, 4 of 16 eyes (25%; 95% CI, 7%-52%) treated with 0.125 mg, 8 of 24 eyes (33%; 95% CI, 16%-55%) treated with 0.063 mg, and 0 (0%; 95% CI, 0%-31%) of 10 eyes treated with 0.031 mg. By 6 months corrected age, 56 of 61 study eyes had regression of ROP with normal posterior poles, 1 study eye had developed a Stage 5 retinal detachment, and 4 infants had died of preexisting medical conditions.
conclusionsRetinal structural outcomes are very good after low-dose bevacizumab treatment for ROP, although many eyes received additional treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.